<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03823768</url>
  </required_header>
  <id_info>
    <org_study_id>00083855</org_study_id>
    <nct_id>NCT03823768</nct_id>
  </id_info>
  <brief_title>Envarsus Neurotoxicity Burden in Liver Transplant Patients</brief_title>
  <official_title>The Effect of Conversion to Once-Daily Envarsus® on the Neurologic Toxicity Burden in Liver Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Veloxis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare neurologic side effects associated with two immunosuppressant
      medications used in liver transplant patients. The standard therapy of twice daily immediate
      release Tacrolimus will be compared to Envarsus once daily. We hypothesize that Envarsus will
      show a lower rate of neurologic side effects than immediate release tacrolimus.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 31, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in neurotoxicity burden</measure>
    <time_frame>6 months</time_frame>
    <description>Estimate the change from baseline to six months in neurotoxicity burden measured by a composite Patient Global Impression of Improvement score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mean Fahn-Tolosa-Marin (FTM) score</measure>
    <time_frame>6 months</time_frame>
    <description>Estimate the change in the mean FTM score among patients with self-reported tremors from baseline to six months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Neurotoxicity</condition>
  <condition>Liver Transplant; Complications</condition>
  <arm_group>
    <arm_group_label>Arm 1: Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tacrolimus immediate release twice daily for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Envarsus daily for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Envarsus</intervention_name>
    <description>Subjects in this group will take Envarsus daily for 6 months of treatment (goal 24 hour trough: 3-10 ng/mL) +/- adjunctive agent and prednisone.</description>
    <arm_group_label>Arm 2: Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus Immediate release</intervention_name>
    <description>Subjects in this group will take Tacrolimus immediate release for 6 months of treatment (goal 12 hour trough: 3-10 ng/mL) +/- adjunctive agent and prednisone.</description>
    <arm_group_label>Arm 1: Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female adult (≥18 years old) with a history of liver or liver/kidney
             transplant within the first 6 months of transplant.

          2. Patients must be capable of understanding the purposes and risks of the study and have
             the ability to give written informed consent and be willing to participate and comply
             with the study.

        Exclusion Criteria:

          1. Patients will be excluded if they are pregnant or nursing females or males with a
             pregnant female partner

          2. HIV positive (HIV ab +)

          3. Unable to tolerate oral medications

          4. Use of another investigational product within thirty days prior to receiving study
             medication

          5. Moderate acute cellular rejection (RAI ≥ 5) within the past month

          6. A condition that is known to cause tremor such as essential tremor, Parkinson disease,
             or enhanced physiologic tremor.

          7. Patients taking medications known to induce tremors or dopamine blocking agents

          8. A condition or disorder that, in the opinion of the investigator, may adversely affect
             the outcome of the study or the safety of the subject
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Derek Dubay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Taber, PharmD</last_name>
    <phone>843-792-2724</phone>
    <email>taberd@musc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caitlin Schaffner, MPH</last_name>
    <phone>843-792-7558</phone>
    <email>schaffne@musc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Taber, PharmD</last_name>
      <phone>843-792-2724</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 29, 2019</study_first_submitted>
  <study_first_submitted_qc>January 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2019</study_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

